View All

Innovative Vaccines for Clostridium difficile Infection Treatment in the Horizon

Clostridium difficile infection (CDI) has emerged as a significant nosocomial infection over the years with increased incidence, recurrence and need for hospitalization. About 15% to 30% of patients who initially respond to antimicrobial therapy experience recurrent CDI (rCDI). After the first recurrence, the risk ...

Find More

Recurrent Clostridium Difficile Infection (rCDI) Market Outlook, Emerging Therapies, and Epidemiology
Evaluating the Potential of Emerging Therapies for Recurrent Clostridium Difficile Infection (rCDI)

Clostridium difficile Infection (CDI), one of the most common nosocomial and community-acquired infections globally, is a major public health challenge. The Clostridium difficile bacteria are a toxin-producing pathogen that produces two types of toxins: toxin A (an enterotoxin) and toxin B (a cytotoxin). This toxin...

Find More